The cost of Dupixent (dupilumab) for eosinophilic esophagitis (EoE) can vary significantly based on insurance coverage, dosage, and location. Without insurance, a 30-day supply can cost over $3,000 [1]. However, patient assistance programs and insurance plans can substantially reduce out-of-pocket expenses.
How much does Dupixent cost with insurance?
For commercially insured patients, out-of-pocket costs for Dupixent can be as low as $0 per prescription through the Dupixent MyWay Co-pay Card program, subject to program terms and conditions [2]. Eligibility and the exact co-pay amount depend on the specifics of the individual's insurance plan.
Are there programs to help with Dupixent costs?
Yes, Sanofi, the manufacturer of Dupixent, offers the Dupixent MyWay program, which provides support for eligible patients with commercial insurance. This program includes co-pay assistance, with savings of up to $10,000 per year on Dupixent prescriptions. For patients who are uninsured or underinsured, Dupixent MyWay may also offer free medicine programs [2].
How is Dupixent prescribed for EoE?
Dupixent is indicated for the treatment of EoE in patients aged 12 years and older. The recommended dosage is an initial 300 mg dose, followed by 300 mg every other week [3]. This dosing regimen is administered via subcutaneous injection.
What is the mechanism of action for Dupixent?
Dupixent is a monoclonal antibody that inhibits the signaling of two key cytokines, IL-4 and IL-13, which are central drivers of the Type 2 inflammation implicated in EoE [4]. By blocking these pathways, Dupixent helps to reduce eosinophilic inflammation in the esophagus [4].
When did Dupixent get approved for EoE?
Dupixent received FDA approval for the treatment of eosinophilic esophagitis (EoE) in adults and children aged 12 years and older in June 2022 [5].
What are the clinical trial results for Dupixent in EoE?
Clinical trials demonstrated that Dupixent significantly reduced esophageal inflammation and improved key clinical endpoints in patients with EoE. For instance, in the OPTIMA study, Dupixent met its primary endpoint, showing a significantly higher percentage of patients achieving histologic disease remission compared to placebo [6]. Patients treated with Dupixent also showed significant improvements in symptom severity as measured by the EoE Activity and Symptom Questionnaire (EASQ) [6].
Are there alternative treatments for EoE?
Other treatment approaches for EoE may include dietary modifications (such as elimination diets), swallowed topical corticosteroids, and proton pump inhibitors (PPIs). However, for many patients, these options may not provide sufficient symptom relief or disease control, leading to the need for advanced therapies like Dupixent [4].
What is the patent status of Dupixent?
Dupixent (dupilumab) is protected by multiple patents. Information on specific patent expiry dates and any ongoing patent litigation can be found on resources like DrugPatentWatch.com [7].
How does Dupixent compare to other biologics?
Dupixent is a biologic therapy targeting IL-4 and IL-13. While other biologics exist for different inflammatory conditions, Dupixent is specifically approved for EoE and targets the underlying Type 2 inflammation characteristic of this disease. Its mechanism is distinct from therapies that target other inflammatory pathways.
---
Sources:
[1] https://www.goodrx.com/dupilumab
[2] https://www.dupixent.com/coverage-and-savings/dupixent-myway
[3] https://www.dupixent.com/hcp/eosinophilic-esophagitis
[4] https://www.dupilumab.com/mechanism-of-action
[5] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dupienit-dupilumab-treatment-eosinophilic-esophagitis
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa2114867
[7] https://drugpatentwatch.com/